[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552237":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":26,"studyPopulation":27,"armGroups":28,"interventions":38,"overallOfficials":46,"centralContacts":50,"locations":56,"responsibleParty":73,"collaborators":22,"id":76,"slug":22,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":22,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":22,"studyType":88,"phases":22,"briefSummary":89,"conditions":90,"keywords":22,"overallStatus":92,"whyStopped":22,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Dongzhimen Hospital, Beijing","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":22},[9],{"measure":10,"description":11,"timeFrame":12},"Sensitivity, specificity, and area under the ROC curve of molecular features of Phlegm-heat syndrome in ischemic stroke","Sensitivity, specificity, and area under the ROC curve of molecular features of Phlegm-heat syndrome in ischemic stroke.\n\nThe molecular characteristics of phlegm-heat syndrome in ischemic stroke include but are not limited to matrix metalloproteinase 9, mitogen-activated protein kinase 1, interleukin 6, and tumor necrosis factor.","Baseline",[14,18],{"measure":15,"description":16,"timeFrame":17},"Proportion of patients independent","Proportion of patients independent is defined as the modified Rankin Scale score of 0, 1, or 2.","90 days",{"measure":19,"description":20,"timeFrame":21},"National Institute of Health Stroke Scale","The National Institute of Health Stroke Scale (NIHSS) ranges from 0 to 42, with higher scores indicating more severe neurological deficits.","Baseline, 7 days and 10 days after stroke onset.",null,{"allocation":22,"interventionModel":22,"interventionModelDescription":22,"primaryPurpose":22,"observationalModel":24,"timePerspective":25,"maskingInfo":22},"COHORT","PROSPECTIVE","This is a cohort study in patients with acute ischemic stroke. The demographic characteristics, Traditional Chinese Medicine (TCM) syndromes, and other baseline information will be recorded. At the same time, baseline peripheral blood will be collected. These participants will be followed up to 90 days of onset, and 90-day modified Rankin scale (mRS) scores will be assessed. The collected blood samples will be tested by multi-factor detection technology for candidate biomarkers.","Patients aged 18 to 80 years with acute ischemic stroke within 72 hours of onset.",[29,34],{"label":30,"type":22,"description":31,"interventionNames":32},"Phlegm-heat syndrome","Phlegm-heat syndrome: the score of \"Phlegm-dampness syndrome\" ≥10 and the score of \"Internal fire syndrome\" ≥10 in Diagnostic Scale for Syndrome Elements of Ischemic Stroke.",[33],"Drug: Guideline-based treatment",{"label":35,"type":22,"description":36,"interventionNames":37},"Non-phlegm-heat syndrome","Non-phlegm-heat syndrome: the score of \"Phlegm-dampness syndrome\" \\\u003C10 and the score of \"Internal fire syndrome\" \\\u003C10 in Diagnostic Scale for Syndrome Elements of Ischemic Stroke.",[33],[39],{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":44},"DRUG","Guideline-based treatment","Guideline-based treatment includes anti-platelet therapy, control of vascular risk factors, and so on.",[35,30],[45],"Routine care",[47],{"name":48,"affiliation":5,"role":49},"Ying Gao, M.D.","PRINCIPAL_INVESTIGATOR",[51],{"name":52,"role":53,"phone":54,"phoneExt":22,"email":55},"Xinxing Lai, M.D.","CONTACT","8615901111280","new-star@163.com",[57],{"facility":58,"status":22,"city":59,"state":60,"zip":61,"country":62,"countryCode":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"Dongzhimen Hospital","Beijing","Beijing Municipality","100700","China","CN",{"type":65,"coordinates":66},"Point",[67,68],116.39723,39.9075,{"lat":68,"lon":67},[71],{"name":52,"role":53,"phone":72,"phoneExt":22,"email":55},"08615901111280",{"type":49,"investigatorFullName":74,"investigatorTitle":75,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"Ying Gao","Professor","100552237",false,"NCT06470477","Molecular Characteristics of Phlegm-heat Syndrome in Ischemic Stroke","Molecular Characteristics of Phlegm-heat Syndrome in Ischemic Stroke: A Cohort Study","Inclusion Criteria:\n\n* Acute ischemic stroke.\n* Symptom onset within 72 hours.\n* Diagnosis of phlegm-heat syndrome or non-phlegm-heat syndrome.\n* Male or female ≥18 years and ≤ 80 years.\n* With written informed consent.\n\nExclusion Criteria:\n\n* Acute infectious diseases or acute exacerbations of chronic diseases within one month before enrollment.\n* Patients has previous stroke.\n* Other conditions that lead to motor dysfunction (e.g., severe osteoarthritis, rheumatoid arthritis).\n* Renal or hepatic insufficiency, tumors, immune diseases, severe underlying diseases.\n* Other conditions that affect the collection and evaluation of clinical information (e.g., severe aphasia, mental illness).","ALL","18 Years","80 Years",{"count":86,"type":87},84,"ESTIMATED","OBSERVATIONAL","The molecular characteristics of ischemic stroke with phlegm-heat syndrome and candidate biomarkers were identified based on multi-omics data. The main purpose of this study is to validate the molecular characteristics and biomarkers of phlegm-heat syndrome in ischemic stroke, and to demonstrate the association of biomarkers with clinical outcomes.",[91],"Ischemic Stroke, Acute","NOT_YET_RECRUITING","2024-06-17",{"date":95,"type":96},"2024-06-24","ACTUAL",{"date":98,"type":87},"2024-06-20",{"date":100,"type":87},"2024-12-31",{"name":5,"class":6},1]